研究单位：[1]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[2]Chinese Cooperative Group of Liver Cancer (CCGLC)[3]Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province[4]The Second Affiliated Hospital of Fujian Medical University[5]Geneplus-Beijing Co. Ltd.[6]Haplox Biotechnology Co., Ltd.[7]The Second Affiliated Hospital of Fujian Medical University,Quanzhou,Fujian,China[8]Optical Valley branch of Tongji hospital,Wuhan,Hubei,China,430073[9]Sino-French branch of Tongji hospital,Wuhan,Hubei,China
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of transarterial chemoembolization (TACE), Anti-VEGF antibodies or pan-target anti-angiogenic drugs, and anti-PD-1/ PD-L1 antibody for advanced hepatocellular carcinoma which initially unsuitable for the radical therapy, including resection, transplantation, or ablation.
